Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) — two of the key ingredients of marijuana — are effective in reducing spasticity and improving mobility among patients with multiple sclerosis (MS), according to a new research review.

eScience News reported Dec. 3 that researchers from the Global Neuroscience Initiative Foundation conducted a review of previously published research studies and concluded that THC and CBD extracts were effective treatments for MS symptoms, albeit with side-effects like intoxication.

“Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief,” said researcher Shaheen Lakhan. “The therapeutic potential of cannabinoids in MS is comprehensive and should be given considerable attention.”

The review was published in the journal BMC Neurology.